News - Part 244

Effects of Ingesting Eye Drops – Risks, Symptoms, and Treatment Options

Effects of ingesting eye drops When it comes to eye drops, they are intended for topical use, meaning they are designed to be applied to…

Understanding the Dry Eye Drops Recall – Alternatives and Recommendations for Post-Surgery Care

Background on Dry Eye Drops Dry eye drops, also known as artificial tears, are a common over-the-counter remedy for dry eye syndrome. This condition occurs…

Recent Eye Drop Recall – Brands, Products, and Safety Guidelines to Avoid Vision Issues

Overview of Recent Eye Drop Recall Incidents in the US Eye drop recalls have garnered significant attention in the United States due to safety concerns…

Understanding the Duration of Eye Drops Treatment for Pink Eye – Guidelines and Recommendations

Duration of Treatment Understanding the recommended duration of using eye drops for pink eye is crucial for effective management of the condition. The duration of…

Where to Find Rohto Eye Drops – A Complete Guide to Buying Rohto Products in Stores and Online

Where to Find Rohto Eye Drops at Local Pharmacies When looking for Rohoto eye drops, local pharmacies can be a convenient option. The following drugstore…

Understanding the Dangers of Misusing Eye Drops – Risks, Side Effects, and Prevention

Effects of using too many eye drops Using too many eye drops can have negative effects on your eyes and overall health. While eye drops…

Inotek Pharmaceuticals’ Novel Glaucoma Candidate, INO-8875, Significantly Reduces Intraocular Pressure in Phase 1/2 Study

— INO-8875 represents new mechanism of action to treat glaucoma by targeting the trabecular meshwork — LEXINGTON Mass., — June 25, 2009 — Inotek Pharmaceuticals…

Inotek Pharmaceuticals Raises $21 Million to Support Ongoing Clinical Development of Trabodenoson, a Novel Eye Drop for the Treatment of Glaucoma

— Phase 2 study to evaluate trabodenoson in combination with latanoprost expected to begin in 2013 — LEXINGTON, MA — September 27th, 2013 — Inotek…

Inotek Pharmaceuticals’ Novel Glaucoma Candidate, INO-8875, Selected for Presentation at the ARVO 2009 Annual Meeting

LEXINGTON Mass.,– April 28, 2009 Inotek Pharmaceuticals today announced that preclinical data supporting the Company’s lead clinical-stage drug candidate in glaucoma, INO-8875, will be presented…

Inotek Pharmaceuticals Presents Preclinical Data in Support of Novel Glaucoma Candidate, INO-8875 at ARVO

INO-8875 currently in Phase 1/2 clinical trial, results anticipated mid-2009 LEXINGTON Mass.,– May 6, 2009 Inotek Pharmaceuticals today presented positive preclinical results supporting the Company’s…